Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 11/11/08 → 11/11/11 |
Funding
- ICON Clinical Research, LLC (VX08-950-111)
- Vertex Pharmaceuticals Incorporated (VX08-950-111)
Prot# VX08-950-111: A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) While Receiving Telaprevir, P
- Flamm, Steven L (PD/PI)
Project: Research project